GE Healthcare's (GEHC) announced that its Lunar iDXA, a new bone mineral density system designed for the treatment of osteoporosis, has received FDA clearance. The system also enables clinicians to simultaneously assess body composition and ascertain fat distribution. The system is capable of measuring patients up to 400 lbs., which will help clinicians assess and diagnose larger patients, GEHC said.
"The new iDXA provides both excellent image quality and precise bone density measurements to help clinicians diagnose osteoporosis," said Dr. Ken Faulkner, chief scientist, Lunar Business, GEHC, in a release. "The system can also determine regional body fat composition, which is an important indicator of risk for diabetes and cardiovascular disease," Faulkner added.